Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NPM1 mutation
i
Other names:
Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin), Testicular Tissue Protein Li 128, Nucleolar Protein NO38, Numatrin, NPM1, Nucleophosmin 1, Nucleophosmin/Nucleoplasmin Family, Member 1, Nucleolar Phosphoprotein B23
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4869
Related biomarkers:
Expression
Mutation
Fusion
Others
‹
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
NPM-RARA fusion (2)
NPM1-NR4A3 fusion (2)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
NPM-ALK fusion (1)
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
NPM-RARA fusion (2)
NPM1-NR4A3 fusion (2)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
NPM-ALK fusion (1)
›
Related tests:
Xpert® NPM1 Mutation assay
Xpert® NPM1 Mutation assay
Associations
(42)
News
Trials
Search handles
@AaronGoodman33
@AkshaySharmaMD
@AlkaliDr
@CLachowiez
@CanerSaygin
@Daver_Leukemia
@DrHKantarjian
@Dr_AmerZeidan
@GomezDLeonMD
@LeukDocJZ
@PLMcCarthyMD
@TalhaBadarMD
@TapKadia
@albertomussetti
@beatalleukemia
@davidhenrymd
@dawood_findakly
@doctorpemm
@hemedoc
@matthew_mei
@romeerizwan
@smbenlazar
Search handles
@AaronGoodman33
@AkshaySharmaMD
@AlkaliDr
@CLachowiez
@CanerSaygin
@Daver_Leukemia
@DrHKantarjian
@Dr_AmerZeidan
@GomezDLeonMD
@LeukDocJZ
@PLMcCarthyMD
@TalhaBadarMD
@TapKadia
@albertomussetti
@beatalleukemia
@davidhenrymd
@dawood_findakly
@doctorpemm
@hemedoc
@matthew_mei
@romeerizwan
@smbenlazar
Filter by
Latest
8ms
Menin inhibition 1 of most promising new class of agents in AML & are clearly active as single agents in R/R AML w/ NPM1mut or KMT2Ar. @EuniceWangMD & Rich Stone present very exciting data w/ Ziftomenib & Revumenib. Can Ziftomenib overcome Menin resistance mut? @DAVAOnc (@LeukDocJZ)
8 months ago
KMT2A (Lysine Methyltransferase 2A)
|
NPM1 mutation
|
revumenib (SNDX-5613) • ziftomenib (KO-539)
9ms
VEN plus AZA for NPM1mut #AML in molecular failure as bridge-to-SCT: safe and effective strategy with MRD neg of rate 82%. @BrunettiLab @cpapayannidis https://t.co/3w9K7iLSK5 #leusm (@BrJHaem)
9 months ago
NPM1 mutation
10ms
Ziftomenib Induces Clinical Activity in NPM1-mutant R/R AML https://t.co/S5Cg8PxMqu via @targetedonc (@lucy_gorelli)
10 months ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
ziftomenib (KO-539)
10ms
Ziftomenib Generates Durable Responses in NPM1-mutant R/R AML @MassGeneralNews @harvardmed @EHA_Hematology #EHA2023 #leusm https://t.co/h9Ptevk4HJ (@OncLive)
10 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
ziftomenib (KO-539)
10ms
Nigel Russell: AML19 trial, FLAG-Ida GO improve outcome in NPM1 mutated AML, irrespective of FLT3m. #EHA2023 #EHA23 (@TalhaBadarMD)
10 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
10ms
FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL https://t.co/0RM6PpVEyO #EHA23 #AML #leusm (@smbenlazar)
10 months ago
Clinical
|
NPM1 mutation
|
Mylotarg (gemtuzumab ozogamicin)
10ms
ICE +ATRA is a strange Induktion for AML-NPM1mut or did I miss something? (@tcv2509)
10 months ago
NPM1 mutation
11ms
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial https://t.co/TQEOtYoEiI (@albertomussetti)
11 months ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
Mylotarg (gemtuzumab ozogamicin)
11ms
A classical example when the conclusion of study is not consistent with study results. It is the responsibility of editors and reviewers to prevent these statements. GO should not be used in NPM1 mutated AML https://t.co/Rm0N1G4yK4 (@Ali_emia)
11 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
11ms
Does this trial change your practice? Not for me as we were already giving GO with IC only for CBF-AML and not for non-CBF favorable risk #AMLsm such as NPM1-mutated or double/bZip CEBPA patients (@Dr_AmerZeidan)
11 months ago
Clinical
|
NPM1 (Nucleophosmin 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
NPM1 mutation • CEBPA mutation
11ms
Bijoy, we use Neogenomics and I simultaneously send the RAPID AML panel and comprehensive myeloid profiles panel. The rapid panel comes back in around 1 week. Has the main actionable mutations (TP53, CEPBA, NPM1, IDH1/2,, FLT3). I Suggest discussing to get it run (@LFletcherMD15)
11 months ago
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
|
TP53 mutation • NPM1 mutation
11ms
until we have more data my approach would be to top line as myeloid neoplasm w/ NPM1 mut, without specifying MDS or AML. that said, I do believe that NPM1c is an irreversible event in leukemogenesis & these cases will eventually progress to bona fide AML if left untreated. 2/2 (@sanamloghavi)
11 months ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
11ms
challenging case. What is the blast phenotype on flow? You could consider repeating marrow in a couple of weeks but this smells like AML. Recent WHO classification has done away with the blast requirement for NPM1 mutations. Keep us posted. (@aksinghmd)
11 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
11ms
AML regardless if blasts count and VAF. And also I am not very familiar with NPM1 mut-related CHIP. (@CharygulyMD)
11 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
11ms
NPM1 mutations are AML-specific. (@abbaminu1)
11 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
12ms
Overlapping features of therapy-related and de novo NPM1-mutated AML https://t.co/swxFqRQFej ➡️ t-AML with NPM1 and de novo NPM1 AML have overlapping features. ➡️ 3 yr OD for t-NPM1 AML, dn-NPM1 AML and t-AML were 54%, 60%, and 31%, respectively. #leusm #MedTwitter @BloodJournal (@TalhaBadarMD)
12 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
12ms
Overlapping features of therapy-related and de novo NPM1-mutated AML https://t.co/DARsu08XzZ➡️ 3 yr OS for t-NPM1 AML, dn-NPM1 AML and t-AML were 54%, 60%, and 31%, respectively. #leusm #MedTwitter @BloodJournal (@TalhaBadarMD)
12 months ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Good or no good? impact of #NPM1m in r/r #AML. 👉🏻 better ORR that wt-NPM1 👉🏻 poor OS regardless We need to do more for r/r AML @BloodAdvances Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML https://t.co/DrtCaNHRH0 (@AlkaliDr)
1 year ago
Clinical • Clinical data
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
I often think of this study when considering prognosis in older patients with NPM1 mutated AML https://t.co/6t0JpRx9ZG (@CLachowiez)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Whether or not to consider AlloBMT is another question that may or may not impact initial Tx decision. In otherwise favorable risk NPM1 mut AML, I let MRD guide decision to transplant and may not recommend it in this case if MRD-neg CR after induction + consolidation. (@LeukDocJZ)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Interesting results! Not surprised to see Aza/Ven as the dominant choice here. However, in an otherwise fit AML pt ~65 years w/ favorable-risk Dz- induction chemo followed by consolidation is potentially curative (albeit NPM1 mut AML in older adults not as “favorable”). (@LeukDocJZ)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
|
Venclexta (venetoclax) • azacitidine
1year
Hope for refractory/relapsed infant leukemia patients with MLL and AML patients with NPM1 mutation Menin inhibitors 👇 (@Satyayadav__)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
A new wave of 'targeted therapy' in #AML? Revumenib- oral menin inhibitor- in R/R AML w/ NPM1mut or KMT2Ar published in @Nature. Clinical activity striking- 30% CR/CRh in heavily pre-Tx R/R AML. Median time to response = 2 months/median DOR = 9 months. https://t.co/Fceg5GWoIV (@LeukDocJZ)
1 year ago
Clinical
|
KMT2A (Lysine Methyltransferase 2A)
|
NPM1 mutation
|
revumenib (SNDX-5613)
1year
65-70 year old fit patient diagnosed with “MDS” in community due to 15% blasts in diagnostic BM Bx. NGS results NPM1, DNMT3A and IDH2 mutations c/w AML. Received 1 cycle of Aza in community before seeing you. Blood counts stable w/o circulating blasts. You recommend? (@LeukDocJZ)
1 year ago
Clinical • Next-generation sequencing
|
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1)
|
IDH2 mutation • NPM1 mutation • DNMT3A mutation • DNMT3A mutation + IDH mutation
1year
Leukemia docs lets discuss! A 50 year old with FLT3 ITD and NPM1 mutated AML is treated with 7+3+midostaurin achieving CR. Both NPM1 and FLT3 ITD are no longer detectable. Proceeds with ablative MUD. Post allo is still in MRD- CR at day+50 and is doing well. You recommend? (@AaronGoodman33)
1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • NPM1 mutation
|
Rydapt (midostaurin)
1year
Systematic review of alloHSCT for AML NPM1 mutated patients with AML: 769 patients, pooled 2 year OS 71%, EFS 64%, relapse rate 25%. Good outcomes. Hussain Poster 155 #Tandem23 #Leusm #BMTsm (@GomezDLeonMD)
1 year ago
Clinical • Review
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
ELN would call this MDS and WHO calls it AML with NPM1 mut. Either way quality of aspirate and assessment of disease in core is important. NPM1m MDS historically did poor. I would follow AML tx path in this case. (@PratzKW)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
I think practical question is how to treat rather than classification. For me it is aml equivalent with NPM1 mutation and would treat with 7+3 with curative intent, and if MRD cleared might forgot transplant. I suspect if you repeat bmbx in few weeks blasts would be higher (@Dr_AmerZeidan)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification https://t.co/OlyBgcaV9r (@BloodJournal)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
I would go for intensive chemo + FLT3i (preferably Gilt) and then alloSCT. Best chance of curative outcome in this younger patient with AML like mutations. She has NPM1 and per recent ICC and WHO could be considered as an AML defining mutation in any case. (@Daver_Leukemia)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Even if MRD positive, I don’t think HSCT in CR1 in the only way to go. Maintenance can eradicate MRD, especially in NPM1 mut AML. And could be optimized by Ven or FLT3i. In case of relapse, can easily achieve CR2 and proceed with HSCT in CR2, especially with FLT3 mut (Gilt) (@grichardmd)
1 year ago
Clinical • Minimal residual disease
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Per ELN/ICC/WHO 2022, NPM1 mut is defining of AML, irrespective of blast count. Multilineage dysplasia is frequent with NPM1 mut and doesn’t affect prognosis. NRAS in presence of NPM1 is actually favorable. The px impact of NRAS is dependant of co-mutations. (@grichardmd)
1 year ago
NRAS (Neuroblastoma RAS viral oncogene homolog) • NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
This is NPM1mut AML irrespective of blast count and dysplasia is seen in up to 1/4 cases of NPM1mut AML. Also, MLD has no prognostic impact in the presence of NPM1 mutation. I would treat with 7+3+mido, then follow a MRD-guided approach. (@KFHemeOnc)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
NPM1 mutated AML is not uncommon to see background morphological dysplastic changes. That usually don’t change the outcome. NPM1 mutation is one of the pitfall/exception in Using morphology to diagnose AML-MRC in WHO 2017. (@henryhmo)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Yes, NPM1/FLT3-TKD muts did well with mido in RATIFY, but the NRAS mut probably pushes to int risk AML (w/recurrent genetic abnormal, 2022 WHO). Plus 24 yo w/multilineage dysplasia? 🚩🚩 seems like Allo might be best consolidation. What says @sghmd? https://t.co/lFXnzBJAXt (@MDPhD10)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Genomically this is NPM1/FLT-3 TKD mutated AML and should be treated with 3+7+Mido->HiDAC+Mido with MRD-based BMT decision. Overall an excellent outcome is anticipated for this patient. https://t.co/b5Wm6N81DT (@RanjitKSMD)
1 year ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
1/2 7+3+Mido for induction, and HDAraC+Mido based consolidation, as this is AML with rec. gen. abnormalities. Genetically this doesn’t seem to be a secondary disease. The NPM1 co-mutations in this case do not seem to worsen the prognosis as per current data (not FLT3-ITD). (@zucenka)
1 year ago
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Here is another 2 analysis suggesting a highly favourable outcome (n=21, n=16) of NPM1-TKD Co-mutated AML. https://t.co/QqUZqZEgs7 https://t.co/EXtSLZbJeB (@RanjitKSMD)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
This is a young fit pt with ELN fav AML (NPM1 mutant, FLT3 ITD negative), if achieves MRD_neg CR1, would not necessarily txp. NPM1 is now AML defining (regardless of blasts) so standard IC, not HMA/ven (experimental in this setting). (@LuskinMarlise)
1 year ago
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
1year
See https://t.co/kqXiuhflGd "Our findings indicate that NPM1 mutations rather than MLD dictate the distinctive features of NPM1-mutated AML." (@LuskinMarlise)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
I’m late to this discussion so hopefully I’m understanding the question correctly. NPM1 mut AML is notorious for having severe background dysplasia and in this setting dysplasia has no prognostic impact. https://t.co/A8XlfdgQgY (@sanamloghavi)
1 year ago
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
1year
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification https://t.co/EnREV0W3OJ 👉🏾 intensively Rx pts with NPM AML and coexisting adverse-risk CG shared the same unfavorable prognosis as their NPM1 wt counterparts #leusm (@TalhaBadarMD)
1 year ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
NPM1 mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login